EPS for aTyr Pharma, Inc. (LIFE) Expected At $-0.43

February 24, 2018 - By Maria Brooks

 EPS for aTyr Pharma, Inc. (LIFE) Expected At $ 0.43

Analysts expect aTyr Pharma, Inc. (NASDAQ:LIFE) to report $-0.43 EPS on March, 15.They anticipate $0.10 EPS change or 18.87 % from last quarter’s $-0.53 EPS. After having $-0.43 EPS previously, aTyr Pharma, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 1.67% or $0.05 during the last trading session, reaching $2.95. About 80,223 shares traded or 90.70% up from the average. aTyr Pharma, Inc. (NASDAQ:LIFE) has risen 12.96% since February 24, 2017 and is uptrending. It has underperformed by 3.74% the S&P500.

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

Among 7 analysts covering Life Technologies Corp (NASDAQ:LIFE), 1 have Buy rating, 3 Sell and 3 Hold. Therefore 14% are positive. Life Technologies Corp had 13 analyst reports since August 25, 2015 according to SRatingsIntel. On Thursday, March 31 the stock rating was downgraded by William Blair to “Market Perform”. The rating was maintained by BMO Capital Markets on Wednesday, November 1 with “Hold”. The stock has “Hold” rating by Zacks on Tuesday, August 25. JP Morgan downgraded the shares of LIFE in report on Wednesday, December 14 to “Neutral” rating. Citigroup initiated the stock with “Neutral” rating in Wednesday, December 16 report. The rating was maintained by Citigroup on Tuesday, August 16 with “Neutral”. As per Wednesday, February 14, the company rating was downgraded by J.P. Morgan. The stock of aTyr Pharma, Inc. (NASDAQ:LIFE) earned “Underweight” rating by JP Morgan on Wednesday, February 14. The rating was initiated by Piper Jaffray with “Buy” on Thursday, September 7. On Thursday, September 17 the stock rating was downgraded by Zacks to “Sell”.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases. The company has market cap of $87.79 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. It currently has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

More notable recent aTyr Pharma, Inc. (NASDAQ:LIFE) news were published by: Globenewswire.com which released: “aTyr Pharma Announces Leadership Transition” on November 01, 2017, also Globenewswire.com with their article: “aTyr Pharma Announces First Quarter 2017 Operating Results” published on May 11, 2017, Globenewswire.com published: “aTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference” on November 21, 2017. More interesting news about aTyr Pharma, Inc. (NASDAQ:LIFE) were released by: Prnewswire.com and their article: “aTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J …” published on September 21, 2016 as well as Prnewswire.com‘s news article titled: “aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors” with publication date: April 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: